These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1262 related articles for article (PubMed ID: 826316)

  • 1. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
    Johnson RK; Ovejera AA; Goldin A
    Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
    Johnson RK; Chitnis MP; Embrey WM; Gregory EB
    Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.
    Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M
    Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative experimental study of the antileukemia activity of carminomycin and rubomycin].
    Khanykova OK; Vinogorova GF
    Antibiotiki; 1977 Sep; 22(9):846-52. PubMed ID: 911158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Models of preclinical studies of anthracyclines].
    Fizames C
    Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 9. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M; Komeshima N; Nakajima S; Tsuruo T
    Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.
    Schwartz HS; Grindey GB
    Cancer Res; 1973 Aug; 33(8):1837-44. PubMed ID: 4720795
    [No Abstract]   [Full Text] [Related]  

  • 11. [Preparation of dihydrocarminomycin and a comparison of its antitumor activity with the activity of carminomycin].
    Povarov LS; Shorin VA; Bazhanov VS; Shepelevtseva NG
    Antibiotiki; 1976 Nov; 21(11):1008-11. PubMed ID: 1037188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New anthracyclines].
    Ogawa M; Ariyoshi Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):27-33. PubMed ID: 8422185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
    Schwartz HS
    Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
    [No Abstract]   [Full Text] [Related]  

  • 14. Antitumor activity and preliminary drug disposition studies on chartreusin (NSC 5159).
    McGovren JP; Neil GL; Crampton SL; Robinson MI; Douros JD
    Cancer Res; 1977 Jun; 37(6):1666-72. PubMed ID: 870180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapeutic effects of compound 593A (NSC-135758) on mouse leukemias and some transplanted animal tumors.
    Tarnowski GS; Schmid FA; Hutchison DJ; Stock CC
    Cancer Chemother Rep; 1973 Feb; 57(1):21-7. PubMed ID: 4704098
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic performance of carminomycin-cyclophosphamide against L1210 leukemia.
    Avery TL; Cruze PG
    Cancer Res; 1978 Sep; 38(9):2892-5. PubMed ID: 679196
    [No Abstract]   [Full Text] [Related]  

  • 17. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
    Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
    Corbett TH; Griswold DP; Mayo JG; Laster WR; Schabel FM
    Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
    Lepri E; Menconi E; Barzi AM
    Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
    Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.